Zhejiang Hisoar Pharmaceutical Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Guorui Xu

Algemeen directeur

CN¥1.0m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	10yrs
Eigendom CEO	0.03%
Management gemiddelde ambtstermijn	10yrs
Gemiddelde ambtstermijn bestuur	2.4yrs

Recente managementupdates

Recent updates

CEO

Guorui Xu (47 yo)

10yrs

Tenure

CN¥1,000,600

Compensatie

Mr. Guorui Xu serves as Non-Independent Director at Zhejiang Hisoar Pharmaceutical Co., Ltd. since November 30, 2022 and serves as its General Manager. He had been Deputy General Manager at Zhejiang Hisoar...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Guorui Xu	GM & Director	10yrs	CN¥1.00m	0.028% CN¥ 2.7m
Bing Yao	Vice President	1.1yrs	CN¥1.00m	geen gegevens
Wen Hua Mao	Deputy General Manager	11.3yrs	CN¥600.80k	0.085% CN¥ 8.0m
Haiyan Zhou	Accounting Supervisor	no data	geen gegevens	geen gegevens
Qing Pan	Vice President	no data	CN¥350.70k	geen gegevens

10.0yrs

Gemiddelde duur

47yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 002099 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 10 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Guorui Xu	GM & Director	2yrs	CN¥1.00m	0.028% CN¥ 2.7m
Bing Yao	Vice President	5yrs	CN¥1.00m	geen gegevens
Wei Zhong Gong	Member of the Supervisory Board	12.1yrs	geen gegevens	geen gegevens
Yangchao Wang	Chairman	5yrs	CN¥608.00k	0.13% CN¥ 12.1m
Minjie Chen	Employees Representative Chairman of Supervisory Board	5yrs	geen gegevens	geen gegevens
Jinyun Hu	Non-Employee Supervisor	2.8yrs	geen gegevens	geen gegevens
Hong Tao	Non-Independent Director	2yrs	CN¥48.30k	geen gegevens
Yongping Yu	Independent Director	2yrs	CN¥80.00k	geen gegevens
Jianmin Qian	Independent Director	2yrs	CN¥6.70k	geen gegevens
Chao Liang	Independent Director	2yrs	CN¥6.70k	geen gegevens

2.4yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 002099 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.4 jaar), wat duidt op een nieuw bestuur.

Zhejiang Hisoar Pharmaceutical Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Zhejiang Hisoar Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024

Zhejiang Hisoar Pharmaceutical Co., Ltd. Elects Tao Hong as Non-Independent Director; and Yu Yongping, Qian Jianmin and Liang Chao as Independent Directors

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released

Zhejiang Hisoar Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: EPS: CN¥0.003 (vs CN¥0.013 loss in 2Q 2023)

Zhejiang Hisoar Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Third quarter 2023 earnings released: CN¥0.03 loss per share (vs CN¥0.021 profit in 3Q 2022)

Zhejiang Hisoar Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024

Zhejiang Hisoar Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 29, 2024

Zhejiang Hisoar Pharmaceutical Co., Ltd. (SZSE:002099) announces an Equity Buyback for CNY 30 million worth of its shares.

Zhejiang Hisoar Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 29, 2024

Third quarter 2023 earnings released: CN¥0.03 loss per share (vs CN¥0.021 loss in 3Q 2022)

New minor risk - Share price stability

Zhejiang Hisoar Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 31, 2023

Second quarter 2023 earnings released: CN¥0.013 loss per share (vs CN¥0.061 profit in 2Q 2022)

Zhejiang Hisoar Pharmaceutical Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 24 May 2023

Zhejiang Hisoar Pharmaceutical Co., Ltd. Approves the Profit Distribution Proposal for 2022

First quarter 2023 earnings released: EPS: CN¥0.02 (vs CN¥0.05 in 1Q 2022)

Zhejiang Hisoar Pharmaceutical Co., Ltd. Elects Tao Hong as Non-Independent Director; and Yu Yongping, Qian Jianmin and Liang Chao as Independent Directors

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.021 (vs CN¥0.01 in 3Q 2021)

Zhejiang Hisoar Pharmaceutical Co., Ltd. Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 25 May 2022

Zhejiang Hisoar Pharmaceutical Co., Ltd. Approves Dividend for 2021

Less than half of directors are independent

Zhejiang Hisoar Pharmaceutical Co., Ltd. Proposes Cash Dividend for 2021

Full year 2021 earnings released: EPS: CN¥0.06 (vs CN¥0.20 in FY 2020)

Third quarter 2021 earnings released: EPS CN¥0.01 (vs CN¥0.06 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.002 (vs CN¥0.10 in 2Q 2020)

Investor sentiment deteriorated over the past week

Zhejiang Hisoar Pharmaceutical Co., Ltd. Announces Dividend for 2020

Full year 2020 earnings released: EPS CN¥0.20 (vs CN¥0.48 in FY 2019)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Market bids up stock over the past week

New 90-day high: CN¥8.53

Third quarter earnings released

Zhejiang Hisoar Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 27, 2020

First half earnings released

Zhejiang Hisoar Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020

New 90-day high - CN¥8.89

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd